Drug Profile
Toripalimab - Shanghai Junshi Biosciences
Alternative Names: Anti-PD1 monoclonal antibody - Shanghai Junshi Biosciences; CHS-007; JS 001; JS-001sc; LOQTORZI; SO-001; TAB-001; Terepril monoclonal antibody; toripalimab-tpzi; Treipril monoclonal antibody; Treprizumab; Treprizumab - Shanghai Junshi Biosciences; Tripleitriumab; Triprizumab; TuoyiLatest Information Update: 09 Apr 2024
Price :
$50
*
At a glance
- Originator Elpiscience Biopharmaceuticals; Shanghai Junshi Biosciences
- Developer Ascentage Pharma; Coherus BioSciences; Fudan University; GenFleet Therapeutics; HUTCHMED; I-MAB Biopharma; Peking Union Medical College Hospital; Peking University; RemeGen; Shanghai Junshi Biosciences; Sun Yat-Sen University; Suzhou Yasheng Pharmaceutical; Xiangya Hospital of Central South University
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Malignant melanoma; Nasopharyngeal cancer; Non-small cell lung cancer; Squamous cell cancer; Urogenital cancer
- Registered Renal cancer
- Preregistration Small cell lung cancer; Triple negative breast cancer
- Phase III Gastric cancer; Hodgkin's disease; Liver cancer; Neuroendocrine tumours
- Phase II Biliary cancer; Bladder cancer; Cancer; Colorectal cancer; Solid tumours; Thyroid cancer
- Phase I/II Head and neck cancer; Liposarcoma; Lung cancer
- No development reported Alveolar soft part sarcoma; Lymphoma
Most Recent Events
- 07 Apr 2024 Registered for Renal cancer (Combination therapy, First-line therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in China (IV)
- 06 Feb 2024 Launched for Non-small cell lung cancer (Combination therapy, Late-stage disease, Neoadjuvant therapy) in China (IV) before January 2024
- 06 Feb 2024 Launched for Non-small cell lung cancer (Late-stage disease, Monotherapy, Adjuvant therapy) in China (IV) before January 2024